Biogen Inc BIIB

NASDAQ US Health Care Biotechnology

$227.60 ▲ +0.55% (+$1.24)

Index member: S&P 500

Open $228.27

Prev Close $226.36

Day Range $223.76 – $228.92

52W Range $135.39 – $229.19

Market Cap $33.45B

P/E (TTM) 39.87

Beta 0.12

EPS (TTM) $5.65

📋 Company Profile

Industry	Biotechnology
Sector	Health Care
Country	US
Exchange	NASDAQ NMS - GLOBAL MARKET
Currency	USD
IPO Date	1991-09-17
Shares Out.	147,750,000
Website	biogen.com/ ↗
Phone	13023513367
Employees	7,500
Revenue	$2.74B
Gross Profit	$1.96B
Net Income	$97.5M
Free Cash Flow	$2.70B
Total Assets	$32.09B
Total Liabilities	$13.24B
Equity	$18.85B

About Biogen Inc

Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 40% of total revenue in 2025. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (19% of total in 2025), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).

Biogen Inc is a publicly traded company under the ticker symbol BIIB on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.